热毒宁联合甲泼尼龙治疗重症新型冠状病毒肺炎临床疗效评价  

Clinical Efficacy of Reduning Injection Combined with Methylprednisolone in the Treatment of Severe Coronavirus Disease 2019

作　　者：秦娅蓝 宋玉燕[2] 周璐[2] 崔勇[3] 张安[1] QIN Yalan;SONG Yuyan;ZHOU Lu;CUI Yong;ZHANG An(The Second Affiliated Hospital of Chongqing Medical University,Chongqing,China 400010;Chongqing Public Health Medical Treatment Center,Chongqing,China 400036;The Three Gorges Central Hospital of Chongqing,Chongqing,China 404000)

机构地区：[1]重庆医科大学附属第二医院,重庆400010 [2]重庆市公共卫生医疗救治中心,重庆400036 [3]重庆三峡中心医院,重庆404000

出　　处：《中国药业》2020年第9期19-22,共4页China Pharmaceuticals

基　　金：重庆市科学技术局新冠肺炎疫情应急科技攻关专项(cstc2020jscx-fyzx0103)。

摘　　要：目的探讨热毒宁联合甲泼尼龙对重症新型冠状病毒肺炎(COVID-19)的临床疗效。方法回顾性分析2020年1月至3月重庆市收治的首次确诊重症COVID-19的部分患者病历资料。将患者分为热毒宁联合甲泼尼龙组(A组)和甲泼尼龙组(B组),比较两组患者治疗前后氧合指数和白细胞(WBC)、白细胞介素(IL)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、降钙素原(PCT)等炎性因子水平,以及住院时间、入住重症监护室(ICU)时间、病毒核酸转阴时间的差异。结果与B组比较,治疗后A组患者WBC,IL-6,IL-17,CRP水平明显降低(P<0.05),IL-4水平明显升高(P<0.05),且住院时间、入住ICU时间明显缩短(P<0.05)。结论热毒宁联合甲泼尼龙治疗重症COVID-19,可显著降低患者炎症水平及住院时间,具有一定临床意义。Objective To investigate the clinical efficacy of Reduning Injection combined with methylprednisolone in the treatment of severe coronavirus disease 2019(COVID-19).Methods The medical records of partial patients with severe COVID-19 diagnosed for the first time in Chongqing from January to March 2020 were analyzed retrospectively.The patients were divided into Reduning Injection combined with methylprednisolone group(group A)and methylprednisolone group(group B).Before and after treatment,the difference of the oxygenation indexes and inflammatory factors such as white blood cell(WBC),interleukin(IL),tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)and procalcitonin(PCT),the length of hospital stay,the length of Intensive Care Unit(ICU)stay and turning-to-negative time of virus nucleic acid were compared between the two groups.Results Compared with group B after treatment,the levels of WBC,IL-6,IL-17 and CRP in group A were significantly lower(P<0.05),the level of IL-4 in group A was significantly higher(P<0.05),and the length of hospital stay and ICU stay in group A was significantly shorter(P<0.05).Conclusion Reduning Injection combined with methylprednisolone in the treatment of patients with severe COVID-19 can significantly reduce the levels of inflammatory factors and the length of hospital stay,which has certain clinical significance.

关 键 词：新型冠状病毒肺炎 热毒宁 甲泼尼龙 临床疗效 

分 类 号：R459.9[医药卫生—治疗学] R243[医药卫生—临床医学]